Manufacturer
84 recalls in our database name Teva Pharmaceuticals USA, Inc. as the manufacturing or recalling firm.
Of the 84 recalls from Teva Pharmaceuticals USA, Inc. we have scored against our rubric, 0 (0%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 9 (11%) are Severe.
The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.
Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.
Teva Pharmaceuticals is recalling 175,392 bottles of Trazodone Hydrochloride 50 mg tablets because they may contain foreign tablets or capsules.
Teva Pharmaceuticals USA, Inc. is recalling 2,200 kits of Octreotide Acetate for Injectable Suspension (30 mg) due to quality system deficiencies that affect sterility assurance. The recall affects all lots nationwide.
Teva Pharmaceuticals is recalling Claravis (isotretinoin) 10 mg capsules due to failure to meet impurity specifications. The affected lots were distributed nationwide in the USA, Puerto Rico, and the Virgin Islands.
Teva is recalling three lots of Isotretinoin Capsules, USP, 40 mg because the product was found to be superpotent and subpotent. 8,376 packages are affected.
Teva is recalling three lots of Isotretinoin Capsules, USP, 30 mg because the product was found to be superpotent and subpotent. 21,984 packages are affected.
Teva is recalling two lots of Clonidine Transdermal System, USP, 0.1 mg/day, citing CGMP deviations involving the use of an unapproved raw material. 124,054 cartons are affected.
Teva is recalling three lots of Clonidine Transdermal System, USP, 0.3 mg/day, citing CGMP deviations involving the use of an unapproved raw material. 113,943 cartons are affected.
Teva is recalling two lots of Clonidine Transdermal System, USP, 0.2 mg/day, citing CGMP deviations involving the use of an unapproved raw material. 62,136 cartons are affected.
Teva is recalling nine lots of Octreotide Acetate for Injectable Suspension 20 mg after quality system deficiencies were identified during an FDA inspection at the contract manufacturer.
Teva is recalling twelve lots of Octreotide Acetate for Injectable Suspension after quality system deficiencies were identified during an FDA inspection at the contract manufacturer.
Teva is recalling two lots of Octreotide Acetate for Injectable Suspension 10 mg after quality system deficiencies were identified during an FDA inspection at the contract manufacturer.
Teva Pharmaceuticals is recalling six lots of Metoprolol Succinate Extended-Release Tablets 50 mg after the product failed dissolution specifications.
Teva Pharmaceuticals is recalling six lots of Metoprolol Succinate Extended-Release Tablets 25 mg after the product failed dissolution specifications.
Teva Pharmaceuticals is recalling three lots of Metoprolol Succinate Extended-Release Tablets 200 mg after the product failed dissolution specifications.
Teva Pharmaceuticals is recalling six lots of Metoprolol Succinate Extended-Release Tablets 100 mg after the product failed dissolution specifications.
Teva Pharmaceuticals USA is recalling 15,944 cartons of Testosterone Gel 1% unit-dose packets because a defect in the side-seal allows leakage of product.
Teva Pharmaceuticals USA is recalling 4,680 cartons of Amoxicillin and Clavulanate Potassium for Oral Suspension 200 mg/28.5 mg per 5 mL because the clavulanate component is subpotent.
Teva Pharmaceuticals USA is recalling 181,659 bottles of Prazosin Hydrochloride Capsules 1 mg because test results for N-nitroso Prazosin impurity C exceeded the acceptable intake limit.
Teva Pharmaceuticals USA is recalling 107,673 units of Prazosin Hydrochloride Capsules 5 mg because test results for N-nitroso Prazosin impurity C exceeded the acceptable intake limit.
Teva Pharmaceuticals USA is recalling 291,512 bottles of Prazosin Hydrochloride Capsules 2 mg because test results for N-nitroso Prazosin impurity C exceeded the acceptable intake limit.
Teva Pharmaceuticals USA, Inc. is recalling Metoclopramide Tablets, USP 10 mg due to the presence of foreign tablets or capsules in the product. The affected lot is distributed nationwide.
Teva Pharmaceuticals is recalling Granix injection due to failed stability test results showing one peptide did not meet specification limits.
Teva Pharmaceuticals recalls 7,080 packets of Testosterone Gel nationwide due to higher-than-labeled potency. Patients using the recalled product may receive unintended overdoses.
Teva Pharmaceuticals is recalling Fludrocortisone Acetate Tablets 0.1mg nationwide and in Puerto Rico due to impurities and degradation substances exceeding specification limits.
Teva Pharmaceuticals is recalling 34,448 bottles of Amoxicillin and Clavulanate Potassium Tablets USP (Chewable 400mg/57mg) distributed nationwide due to subpotency. The recall is voluntary and initiated by the firm.
Community-sourced company facts from Wikidata, not from any recall agency. This is background on the corporate entity — it says nothing about the recall(s) listed on this page, which come from the agency source notice above.
Teva Pharmaceuticals CR
company in Prague, Czechia
Source: Wikidata (Q41567143), licensed CC0. Wikidata is community-edited and may not reflect the current corporate structure.